

**BioXcel Therapeutics, Inc.**  
555 Long Wharf Drive  
New Haven, CT 06511

November 9, 2023

**Via EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, DC 20549  
Attention: Joshua Gorsky

Re: **BioXcel Therapeutics, Inc.**  
**Registration Statement on Form S-3 Filed November 2, 2023**  
**File No. 333-275261**

To the addressees set forth above:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, BioXcel Therapeutics, Inc. (the "**Company**") hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-275261) be accelerated by the Securities and Exchange Commission to 9:00 a.m. Washington D.C. time on November 14, 2023 or as soon as practicable thereafter.

The Company requests that we be notified of such effectiveness by a telephone call to Keith L. Halverstam of Latham & Watkins LLP at (212) 906-1761 or N. Danny Shulman at (212) 906-4510 and that such effectiveness also be confirmed in writing.

Sincerely,

**BioXcel Therapeutics, Inc.**

By: /s/ Richard Steinhart  
Richard Steinhart  
Chief Financial Officer

cc: Keith L. Halverstam, Latham & Watkins LLP  
N. Danny Shulman, Latham & Watkins LLP

---